Cynapsus Therapeutics Inc.’s (CYNA) pivotal phase III efficacy study of APL-130277 to treat OFF episodes in patients with Parkinson’s disease has enrolled the last patient.
Forex – financial instrument.Forex news
Cynapsus Therapeutics Inc.’s (CYNA) pivotal phase III efficacy study of APL-130277 to treat OFF episodes in patients with Parkinson’s disease has enrolled the last patient.